suffer delhi belli
thesi updat may quick proclaim
death growth engin seen movi
time cover space help put context current
struggl dire standpoint point
high end ms cite technolog gap think fair
critic broadli use term share loss unfair especi
lc uniqu exposur india current u/p
also heard tripl quad soft key product ultim
year typic year pharma capital-expenditure cycl
turn instrument dip core growth thu
camp structur im sure new product
momentum also help said current back-
drop mix fundament reflect valuat
major updat rel debt ebitda
increment leverag use repo share like
place upward pressur wat stock price current level
least provid support convinc make
sens like go destroy valu view
unless continu lag turn ep forecast
move lower conserv core growth outlook
move higher increment repurchas leverag off-set
slightli less oi growth pt move given mix
fundament histor market premium return
typic level reiter rate expect share
ultim bounc today steep correct typic
us biopharma demand continu improv build
 strength led continu growth asia america
notabl out-performance environment research pharma
acceler share repo program includ mm
bring total bn
pleas see analyst certif import disclosur page report evercor isi affili seek busi
compani cover research report investor awar firm may conflict interest could affect object
report investor consid report singl factor make invest decis
lower guidanc due weak biopharma eu
eu gener weak across end market particular pocket
weak biopharma clinic
ta instrument weak due mix order time lead
shipment delay particularli china order sale
process elong may may due trade issu
sale growth expect
continu see strength china nice
improv us pharma weaker
expect perform ta instrument european
instrument flat instrument flat ta instrument
constant currenc lower vs prior
interest lower mm vs mm prior
share lower mm vs mm prior rais
share repo bn vs mm prior anticip
purchas mm
ep lower midpoint vs
constant currenc fx tw vs consensu
continu weak european pharma
continu conservat w/ regard
ep fx hw vs consensu
meaning pick us pharma
asia driven dd growth china off-set modest
strength pharma food chemic
china
ta shipment delay due elong order sale process
monitor trade situat indirect impact demand
india growth modest recoveri normal growth
caus polit uncertainti econom moder
believ india come back eventu
custom patient buyer india typic goe
lt trend line still posit india
cycl
steadi contribut recur rev
america canada latam continu strong
off-set soft us
meaning pick us pharma expect
continu
europ good industri sale off-set lower
pharma
biomed research clinic applic
weak european pharma custom expect
continu
pharma grew dd growth china pick us modest
declin eu pharma well clinic applic
industri grew driven strength chemic analysi
may relat china trade war
 grew due strong growth asia america off-set
european weak
rais fy share repo bn vs mm prior
anticip purchas mm
capit deploy focu share repo along
seek drive net debt ebitda
valuat methodolog base mix discount cash flow analysi rel valuat multipl
risk valuat includ regulatori risk overal market risk well unforeseen event relat individu cover
compani broader sector includ new competit product technolog
laboratori corp america
articl articl
time dissemin octob
analyst luke sergott ross muken primarili respons prepar research report attest follow view
opinion render research report reflect person view subject compani issuer part
research analyst compens directli relat specif recommend view research report
